The U.S. Food and Drug Administration has granted 510(k) clearance for the NovoPen Echo®, the first insulin injection device on the market to combine half-unit dosing with a memory function to help patients manage their diabetes.
Manufacturer Novo Nordisk says the pen represents a significant milestone in insulin delivery, especially for children with diabetes and their caregivers. “It can offer caregivers increased confidence that their children are managing their diabetes appropriately away from home by allowing them to see the amount and time passed since their last dose,” said Camille Lee, senior vice president, Diabetes Marketing, at Novo Nordisk.
Lee said half-unit dose increments allow for finer adjustments, which can be particularly important for children. In addition, different removable skins will be available for a customized look.
The pen, which Novo Nordisk plans to introduce to the U.S. market in 2014, will be available to patients for use with NovoLog® (insulin aspart [rDNA origin] injection) PenFill® cartridges.